Healthcare provider profile · identity verified

Joseph Peter Binfet, M.D.

Family Practice · ROCHESTER, IN · NPI 1457555716

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	662	178
Levothyroxine Sodium	Levothyroxine Sodium	591	143
Lisinopril	Lisinopril	468	128
Amlodipine Besylate	Amlodipine Besylate	453	122
Losartan Potassium	Losartan Potassium	382	105
Rosuvastatin Calcium	Rosuvastatin Calcium	367	112
Pantoprazole Sodium	Pantoprazole Sodium	339	104
Metformin Hcl Er	Metformin Hcl	294	76
Gabapentin	Gabapentin	231	51
Sertraline Hcl	Sertraline Hcl	187	52
Duloxetine Hcl	Duloxetine Hcl	185	46
Metoprolol Succinate	Metoprolol Succinate	184	54
Hydrochlorothiazide	Hydrochlorothiazide	170	50
Pravastatin Sodium	Pravastatin Sodium	160	50
Famotidine	Famotidine	158	49
Simvastatin	Simvastatin	149	43
Allopurinol	Allopurinol	148	43
Omeprazole	Omeprazole	139	39
Montelukast Sodium	Montelukast Sodium	138	42
Albuterol Sulfate Hfa	Albuterol Sulfate	135	58
Fluticasone Propionate	Fluticasone Propionate	131	83
Metformin Hcl	Metformin Hcl	131	43
Alprazolam	Alprazolam	129	23
Tamsulosin Hcl	Tamsulosin Hcl	121	37
Glipizide Er	Glipizide	120	31
Potassium Chloride	Potassium Chloride	120	39
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	116	26
Eliquis	Apixaban	103	27
Azelastine Hcl	Azelastine Hcl	102	66
Metoprolol Tartrate	Metoprolol Tartrate	100	30
Carvedilol	Carvedilol	99	29
Escitalopram Oxalate	Escitalopram Oxalate	97	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	88	24
Furosemide	Furosemide	80	26
Trulicity	Dulaglutide	77	13
Ozempic	Semaglutide	72	15
Clopidogrel	Clopidogrel Bisulfate	66	23
Warfarin Sodium	Warfarin Sodium	66	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	65	13
Prednisone	Prednisone	64	48
Symbicort	Budesonide/Formoterol Fumarate	62	20
Synthroid	Levothyroxine Sodium	60	15
Jardiance	Empagliflozin	59	12
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	51	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	49	suppressed
Spironolactone	Spironolactone	49	14
Trazodone Hcl	Trazodone Hcl	48	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	45	42
Tramadol Hcl	Tramadol Hcl	43	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	42	13
Celecoxib	Celecoxib	42	15
Meloxicam	Meloxicam	40	16
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	11
Pregabalin	Pregabalin	39	suppressed
Alendronate Sodium	Alendronate Sodium	37	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	34	30
Ezetimibe	Ezetimibe	33	13
Lorazepam	Lorazepam	32	suppressed
Lovastatin	Lovastatin	31	suppressed
Breo Ellipta	Fluticasone/Vilanterol	30	suppressed
Cefdinir	Cefdinir	29	26
Valsartan	Valsartan	28	suppressed
Glimepiride	Glimepiride	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Atenolol	Atenolol	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Novolog Flexpen	Insulin Aspart	24	suppressed
Bydureon Bcise	Exenatide Microspheres	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Spiriva Respimat	Tiotropium Bromide	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Sucralfate	Sucralfate	21	11
Arnuity Ellipta	Fluticasone Furoate	20	suppressed
Azithromycin	Azithromycin	19	18
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	13
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Finasteride	Finasteride	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Triazolam	Triazolam	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Calcitriol	Calcitriol	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nystatin	Nystatin	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Pentoxifylline	Pentoxifylline	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error